Artivion, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 02, 2023 at 04:11 pm EDT
Share
Artivion, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 87.85 million compared to USD 76.84 million a year ago. Net loss was USD 9.8 million compared to USD 13.71 million a year ago. Basic loss per share from continuing operations was USD 0.24 compared to USD 0.34 a year ago. Diluted loss per share from continuing operations was USD 0.24 compared to USD 0.34 a year ago.
For the nine months, revenue was USD 260.33 million compared to USD 234.39 million a year ago. Net loss was USD 26.72 million compared to USD 21.36 million a year ago. Basic loss per share from continuing operations was USD 0.65 compared to USD 0.53 a year ago. Diluted loss per share from continuing operations was USD 0.65 compared to USD 0.53 a year ago.
Artivion, Inc. is a medical device company engaged in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease, heart valve disease, aortic aneurysms, and dissections. The Company's segments include Medical Devices and Preservation Services. The Medical Devices segment includes sales of aortic stent grafts, surgical sealants, and On-X. The Preservation Services segment includes services for the preservation of cardiac and vascular implantable human tissues. It has four product families: aortic stent grafts, surgical sealants, On-X mechanical heart valves and related surgical products, and implantable cardiac and vascular human tissues. Aortic stent grafts include aortic arch stent grafts, abdominal stent grafts, and synthetic vascular grafts. Surgical sealants include BioGlue Surgical Adhesive products. It also sells or distributes PhotoFix bovine surgical patches.
ARTIVION, INC. 
